Berrin Erok



In patients with newly diagnosed breast cancer, additional breast lesions with probably benign morphology may cause a difficulty in diagnosis when they  respone to neoadjuvant chemotheraphy. We report a case of contrlateral breast lesion with probably benign morphology,which showed total loss of contrast enhancement after NAC.

Case report

A 41-year-old female patient presented with a palpable left breast mass.Ultrasonography demonstrated 35x25 mm heterogenous hypoechoic mass with indistinct margins,On the right breast, there was a 7x4 mm hypoechoic lesion which was considered as BI-RADS 3 lesion.On breast MR imaging the left breast lesion showed rapid heterogenous enhancement which was considered to be a BI-RADS 5 lesion.The right breast lesion showed progressive contrast enhancement. Tru-cut needle biopsy of the BI-RADS 5 lesion and left axillary LAP revealed out not otherwise specified invasive ductal carcinoma (NOS-IDC) with axillary metastasis. NAC was planned before surgical management. At 6 th month, follow up MRI reveaed out total regression of the left breast BI-RADS 5 lesion with no contrast enhancement.The right sided lesion also showed no contrast enhancement.Although on targeted US this right breast mass was seen as similar with its pre NAC appearance excision of the mass was decided with the malignant lesion at the same operation. Histopathological result of the right breast mass was reported as fibroadenom.



Additional ipsilateral or contralateral breast lesions with otherwise probabbly benign appearance seen on preoperative MRI that respond to NAC in the similar way with the malignant lesion on follow up MR imaging may not be a malignant focus.

Full Text:



Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97(3):188–194.

Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–2685

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.

Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.

Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342–54.

Chen JH, Yu H, Lin M, Mehta RS, Su MY. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson Imaging. 2013;31:1465–71.

Schrading S, Kuhl CK. Breast cancer: Influence of taxanes on response assessment with dynamic contrast-enhanced MR imaging. Radiology. 2015;277:687–96.

Preibsch H, Wanner L, Bahrs SD, Wietek BM, Siegmann-Luz KC, Oberlecher E, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: Correlation with tumour response. Eur Radiol. 2016;26:1590–6.

ACR Practice Parameter for the Performance of Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast. [Last accessed on 2016 Jun 14].

Alberto Bouzón, Benigno Acea,Rafaela Soler, Ángela Iglesias, Paz Santiago, Joaquín Mosquera,Lourdes Calvo,Teresa Seoane-Pillado,Alejandra García.Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients. Radiol Oncol. 2016 Mar 1; 50(1): 73–79.

Sheikhbahaei S, Trahan TJ, Xiao J, et al. FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. Oncologist 2016;21(8):931–939.

Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.Clin Breast Cancer. 2017 Jul;17(4):245-255.

Santamaría G, Bargalló X, Fernández PL, Farrús B, Caparrós X, Velasco M. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response. Radiology. 2017 Jun;283(3):663-672.

Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED,, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.AJR Am J Roentgenol. 2018 Jun;210(6):1376-1385.

Rebecca Leddy, Abid Irshad, Lara Hewett, Heather Collins, Frank Vento, Susan Ackerman, Madelene Lewis. Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?J Clin Imaging Sci. 2016; 6: 39.


  • There are currently no refbacks.

© Copyright PJR 2008-